Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1003

1.

Does the management of bladder perforation during transurethral resection of superficial bladder tumors predispose to extravesical tumor recurrence?

Skolarikos A, Chrisofos M, Ferakis N, Papatsoris A, Dellis A, Deliveliotis C.

J Urol. 2005 Jun;173(6):1908-11.

PMID:
15879773
2.

The actual incidence of bladder perforation following transurethral bladder surgery.

Balbay MD, Cimentepe E, Unsal A, Bayrak O, Koç A, Akbulut Z.

J Urol. 2005 Dec;174(6):2260-2, discussion 2262-3.

PMID:
16280794
3.

Clinical panurothelial disease in patients with superficial bladder tumors: therapeutic implications.

Solsona E, Iborra I, Ricos JV, Monros JL, Rubio J, Almenar S.

J Urol. 2002 May;167(5):2007-11.

PMID:
11956428
4.

Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder.

Zietman AL, Grocela J, Zehr E, Kaufman DS, Young RH, Althausen AF, Heney NM, Shipley WU.

Urology. 2001 Sep;58(3):380-5.

PMID:
11549485
5.

Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.

Kikuchi E, Fujimoto H, Mizutani Y, Okajima E, Koga H, Hinotsu S, Shinohara N, Oya M, Miki T; Cancer Registration Committee of the Japanese Urological Association.

Int J Urol. 2009 Mar;16(3):279-86. doi: 10.1111/j.1442-2042.2008.02235.x. Epub 2009 Jan 20.

6.
7.

The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour.

Solsona E, Iborra I, Rubio J, Casanova J, Almenar S.

BJU Int. 2004 Dec;94(9):1258-62.

8.

Management of low grade papillary bladder tumors.

Herr HW, Donat SM, Reuter VE.

J Urol. 2007 Oct;178(4 Pt 1):1201-5; discussion 1205. Epub 2007 Aug 14.

PMID:
17698090
10.
11.

Prognostic factors of primary transitional cell carcinoma of the upper urinary tract.

Lee SH, Lin JS, Tzai TS, Chow NH, Tong YC, Yang WH, Chang CC, Cheng HL.

Eur Urol. 1996;29(3):266-70; discussion 271.

PMID:
8740029
12.

Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.

Gofrit ON, Shapiro A, Pode D, Sidi A, Nativ O, Leib Z, Witjes JA, van der Heijden AG, Naspro R, Colombo R.

Urology. 2004 Mar;63(3):466-71.

PMID:
15028439
13.
14.

TUR and adjuvant intravesical chemotherapy in T1G3 bladder tumors: recurrence, progression and survival in 137 selected patients followed up to 20 years.

Serretta V, Pavone C, Ingargiola GB, Daricello G, Allegro R, Pavone-Macaluso M.

Eur Urol. 2004 Jun;45(6):730-5; discussion 735-6.

PMID:
15149744
16.

Risk factors for local recurrence in patients with pTa/pT1 urinary bladder cancer.

Jancke G, Damm O, Rosell J, Jahnson S.

Scand J Urol Nephrol. 2008;42(5):417-21. doi: 10.1080/00365590802016302.

PMID:
18609266
17.

Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience.

Kassouf W, Swanson D, Kamat AM, Leibovici D, Siefker-Radtke A, Munsell MF, Grossman HB, Dinney CP.

J Urol. 2006 Jun;175(6):2058-62.

PMID:
16697803
18.
20.

Early complications of endoscopic treatment for superficial bladder tumors.

Collado A, Chéchile GE, Salvador J, Vicente J.

J Urol. 2000 Nov;164(5):1529-32.

PMID:
11025697

Supplemental Content

Support Center